Immunohistochemical expression of internal and external ErbB‐2 domains in invasive breast cancer

[1]  S. Pileri,et al.  Antigen retrieval techniques in immunohistochemistry: comparison of different methods , 1997, The Journal of pathology.

[2]  Y. Yarden,et al.  Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. , 1996, Oncogene.

[3]  Y. Yarden,et al.  Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. , 1996, The American journal of pathology.

[4]  Y. Yarden,et al.  Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2 , 1995, Molecular and cellular biology.

[5]  M. Sliwkowski,et al.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.

[6]  D. Santini,et al.  Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: a useful tool for elucidating its biological behaviour. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Y. Yarden,et al.  Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. , 1994, American journal of clinical pathology.

[8]  D. Birnbaum,et al.  Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation , 1994, The Journal of pathology.

[9]  Y. Yarden,et al.  Neu and its ligands: From an oncogene to neural factors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[10]  P. Robbins,et al.  What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease. , 1993, Pathology, research and practice.

[11]  J. Iglehart,et al.  Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[12]  G. Martinelli,et al.  Demonstration of cytokeratin intermediate filaments in oocytes of the developing and adult human ovary , 1993, Histochemistry.

[13]  P. Maxwell,et al.  C-erbB-2 oncogene product expression depends on tumour type and is related to oestrogen receptor and lymph node status in human breast carcinoma. , 1993, Pathology, research and practice.

[14]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  G. Mills,et al.  Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. , 1992, Cancer research.

[16]  R. Akita,et al.  An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. , 1991, Cancer research.

[17]  T. Perren.  c-erbB-2 oncogene as a prognostic marker in breast cancer. , 1991, British Journal of Cancer.

[18]  I. Ellis,et al.  c-erbB-2 oncoprotein expression in primary and advanced breast cancer. , 1991, British Journal of Cancer.

[19]  W. Carney,et al.  The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. , 1991, The Journal of biological chemistry.

[20]  R. Fourney,et al.  Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. , 1991, Cancer research.

[21]  J. Bacus,et al.  HER-2/neu oncogene expression and proliferation in breast cancers. , 1990, The American journal of pathology.

[22]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[23]  W. Gullick,et al.  NCL‐CB11, a new monoclonal antibody recognizing the internal domain of the c‐erbB‐2 oncogene protein effective for use on formalin‐fixed, paraffin‐embedded tissue , 1990, The Journal of pathology.

[24]  Brian Everitt,et al.  Statistical Methods for Medical Investigations , 1990 .

[25]  W. McGuire,et al.  HER-2/neu oncogene protein and prognosis in breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Quirke,et al.  Pattern of expression of c-erbB-2 oncoprotein in human fetuses. , 1989, British Journal of Cancer.

[27]  W. Gullick,et al.  Neu receptor dimerization , 1989, Nature.

[28]  S. Hirohashi,et al.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. , 1989, Cancer research.

[29]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[30]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[31]  S. Aaronson,et al.  Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene , 1988, Molecular and cellular biology.

[32]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[33]  B. Groner,et al.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.

[34]  J. Yokota,et al.  Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. , 1987, Cancer research.

[35]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[36]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[37]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[38]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[39]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[40]  C. De Potter.  The neu-oncogene: more than a prognostic indicator? , 1994, Human pathology.

[41]  M. Fernö,et al.  ERBB2 amplification in breast cancer with a high rate of proliferation. , 1991, Oncogene.

[42]  R. Dickson,et al.  Genes, oncogenes, and hormones : advances in cellular and molecular biology of breast cancer , 1991 .

[43]  R. Zeillinger,et al.  HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. , 1989, Oncogene.

[44]  W. J. Langford.  Statistical Methods , 1959, Nature.